Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

April 30, 2006

Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG

ziprasidone

Trial Locations (27)

1739

Pfizer Investigational Site, Krugersdorp

Pfizer Investigational Site, Noordheuwel, Krugersdorp

3600

Pfizer Investigational Site, Pinetown, Durban

4094

Pfizer Investigational Site, Bellair, Durban

7925

Pfizer Investigational Site, Observatory, Cape Town

11528

Pfizer Investigational Site, Athens

12462

Pfizer Investigational Site, Athens

13041

Pfizer Investigational Site, Kuwait City

15126

Pfizer Investigational Site, Athens

31451

Pfizer Investigational Site, Khobar

35340

Pfizer Investigational Site, Izmir

41110

Pfizer Investigational Site, Larissa

Unknown

Pfizer Investigational Site, Alexandria

Pfizer Investigational Site, Asyut

Pfizer Investigational Site, Cairo

Pfizer Investigational Site, Tanta

Pfizer Investigational Site, Jordan

Pfizer Investigational Site, Beirut

Pfizer Investigational Site, Ankara

Pfizer Investigational Site, Bursa

Pfizer Investigational Site, Erzurum

Pfizer Investigational Site, Istanbul

Pfizer Investigational Site, Izmir

Pfizer Investigational Site, Manisa

Pfizer Investigational Site, Şişli

Pfizer Investigational Site, Dubai

0208

Pfizer Investigational Site, Garankuwa

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00137020 - Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter